



KIRA PHARMACEUTICALS ANNOUNCES \$53.5 MILLION SERIES B+ FINANCING TO ADVANCE LOGIC DRUG DISCOVERY PLATFORM AND PIPELINE OF COMPLEMENT-TARGETED THERAPIES

CAMBRIDGE, MA and SUZHOU, China (January 7, 2021) – Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced the first closing of an oversubscribed \$53.5 million Series B+ financing. The financing was co-led by RA Capital Management and Vivo Capital, with participation from Foresite Capital and APlus Partners. Existing investors, including Quan Capital and Qiming Venture Partners USA, also participated in the first closing.

“While the complement system has historically been difficult to target given its complexity, we believe our LOGIC drug discovery platform enables us to approach complement mediation in new and different ways, unlocking transformative therapies for patients,” said Frederick Beddingfield, MD, PhD, Chief Executive Officer of Kira Pharmaceuticals. “We are honored to have the support of top-tier global investors as we continue to advance our lead asset P014, a bifunctional biologic entering the clinic soon, and a pipeline of important complement-targeted therapies for patients in need.”

With a therapeutic focus on inflammatory and autoimmune diseases and oncology, Kira has plans to advance three complement-targeted therapies to the clinic over the next 18 months. Kira’s most advanced program, P014, is a first-in-class

biologic molecule with a unique mechanism of action designed to inhibit both upstream and downstream complement targets. By regulating two separate rate-limiting steps in the complement activation cascade critical for disease development, P014 provides a powerful and selective approach to complement inhibition. P014 has also been engineered with an extended half-life and potency, with the opportunity for self-administration at home.

“We are thrilled by the rapid progress Kira Pharmaceuticals has made with its lead program, P014, a therapeutic with a truly novel mechanism of action, that will be advancing into the clinic soon,” said Matthew Hammond, PhD, Principal at RA Capital Management. “With an intelligent drug discovery platform, a broad pipeline of therapies and a top-tier team, we believe Kira is on the leading edge of defining a new way to target complement and provide long-acting immune modulation.”

“We are excited to embark on this partnership with the Kira Pharma team and look forward to the advancement of breakthrough complement therapeutic P014 into the clinic,” said Dandan Dong, PhD., Managing Director at Vivo Capital. “With a world-class management team and a global infrastructure, we believe Kira is in a unique position to leverage its scientific expertise and resources to rapidly bring innovative therapies to patients suffering from complement mediated diseases.”

About Kira Pharmaceuticals

Kira Pharmaceuticals is a biotechnology company developing complement-targeted therapies to treat immune-mediated diseases. Enabled by its LOGIC drug discovery platform, the company is committed to advancing first-in-class and best-in-class therapies to transform the lives of patients with complement-driven diseases. With offices in Cambridge, Massachusetts and an R&D center in Suzhou, China, Kira Pharmaceuticals is committed to establishing a global footprint and advancing life-changing therapies to patients around the world.

For more information, please visit www.kirapharma.com.

2021 年 1 月 7 日

中国苏州；美国剑桥

科越医药宣布获得 5350 万美元的 B+ 轮 1 期 融资 (first closing)，以推进 LOGIC 药物发现平台和补体靶向疗法

科越医药，一家致力于研发新一代补体靶向药物来治疗免疫介导疾病的全球生物技术公司，今天宣布获得 5350 万美元 B+ 轮 1 期融资(first closing)。本期资金由 RA 资本 (RA Capital Management)，维梧资本 (Vivo Capital)，Foresite 资本 (Foresite Capital)和绅湾资本 (APlus Partners) 等全球领先的生命科学风投基金联合提供。现有投资人包括泉创资本 (Quan Capital)，启明创投 (Qiming Venture Partners) 也参与了本期融资。

“科越的创始团队已经开发出一个智能药物发现平台，用于推进开发能克服补体药物发现过程中各种挑战，并且能够以慎密的创新方法调节补体系统的新型抗体药物，”科越医药首席执行官贝丁菲尔德博士 (Frederick Beddingfield, MD, PhD) 说道。“能够得到全球顶尖投资人的支持，助力科越把 P014 推广至临床，提供给急需的患者使用，为此我们倍感荣幸。”

科越计划在未来 18 个月把三种补体靶向疗法推广至临床，重点治疗炎症疾病、自身免疫性疾病和肿瘤。科越最先进的治疗方案是 P014，这是一款全球首创生物药，具有独特的作用机制，旨在同时抑制上游和下游的补体靶点。P014 通过调节对疾病发展至关重要的补体活化级联中的两个单独的限速步骤，以此为补体抑制提供一种强有力且可能更加有选择性的精准治疗方法。P014 还设计有更长的半衰期和效力，从而让患者有可能在家中实现自我给药。

RA Capital 负责人马修·哈蒙德(Matthew Hammond, PhD)博士说：“科越团队以一种真正新颖的作用机制，在推动其领先计划 P014 方面取得的迅速进展令我们感到振奋，”借助智能药物发现平台，产品多样化和顶级团队，我们相信科越在补体靶向疗法和提供长效免疫调节的新疗法方面处于领先地位。”

“我们很高兴与科越团队的合作，期待其将突破性的补体疗法 P014 推向临床，”维梧资本董事总经理董丹丹 (Dandan Dong, PhD) 博士说。“凭借一流的管理团队和中美双边设施，我们相信科越拥有独特科学创新平台技术和跨境资源为患有补体介导疾病的患者尽早提供创新疗法。”

关于科越医药

科越医药是一家致力于开发治疗免疫介导疾病的补体靶向疗法的生物技术公司。公司凭借自己的 LOGIC 药物发现平台，致力于推进首创疗法及最佳疗法，以此彻底改善补体介导疾病患者的生活。科越医药在美国马萨诸塞州剑桥市设有办事处，并且在中国苏州和上海设有研发中心，以此致力于建立全球足迹，在全球推广能够改善患者生活的创新疗法。

更多详情，请访问网址 www.kirapharma.com。

媒体咨询

马溢

yi.ma@kirapharma.com

(86)138-6200-1240